NewAmsterdam says EU CHMP backs Ubeslo, Evlarco cholesterol drugs for approval
NAMS•EU CHMP backs marketing authorization
NewAmsterdam Pharma and Menarini won a positive CHMP opinion backing EU marketing authorization for Ubeslo (obicetrapib) and Evlarco (obicetrapib/ezetimibe).
The recommendation covers primary hypercholesterolemia, including heterozygous familial hypercholesterolemia.
The European Commission decision is expected in 2H 2026.
